Selective estrogen-receptor modulators (SERMs) improve survival in women with breast cancer. There is, however, a need for more-effective SERMs and, most importantly, tissue-targeted alternatives to classical hormone replacement therapy while preventing breast cancer. This article describes how combining a SERM and dehydroepiandrosterone might prevent breast and uterine cancers, while benefiting other tissues affected by the menopause.
